Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX-ECP: ECP vs BAT for ir-Colitis/Hepatitis in Melanoma
NCT07619898Phase 2Not yet recruiting
- Sponsor
- Therakos
- Start
- Jul 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, randomised, open-label trial of methoxsalen in Colitis and hepatitis (2 arms), sponsored by Therakos. Primary endpoint: Proportion of Participants Who are in Steroid-free response at 12 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
methoxsalen
03
Conditions
Colitishepatitis
Beyond the preview
Go deeper on NCT07619898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619898.